Immunotherapy using cytotoxic T cell and peptide vaccine for pancreatic cancer

使用细胞毒性 T 细胞和肽疫苗治疗胰腺癌的免疫疗法

• 批准号: 12557104
• 负责人: OKA Masaaki
• 金额: $ 8.19万
• 依托单位: Yamaguchi University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2000
• 资助国家: 日本
• 起止时间: 2000 至 2002
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-12557104/
• 关键词: pancreatic cancer; CTL; cell therapy; cancer-related peptide; cancer vaccine therapy; dendritic cell; MUC1; ペプチド療法

(1) Fifteen patients (stage III : 4, stage Iva : 8, stage Ivb : 3) with pancreatic cancer were treated by immunotherapy using MUC1-CTL after curative resection. Only one patient had liver recurrence. One year and 2 year survival rate were 80% and 21.4%, respectively. This immunotherapy may prevent liver metastasis after surgery, but can not control local recurrence.(2) We performed phase I study of cancer peptide vaccine therapy for HLA-02 and -24 patients with unresectable pancreatic cancer. Three mg of peptides were administered with Freund's incomplete adjuvant subcutaneously. No sever adverse effect was observed. Seven of 10 patients had redness and edema in the injection sites. Three of 10 patients had NC and 7 had PD. One NC patient is still alive for 12 month. This vaccine therapy may be effective to control local lesion including regional lymph node metastasis.

(1)15例(III期4例，IVA期8例，IVB期3例)胰腺癌根治性切除后应用MUC1-CTL免疫治疗。只有一名患者出现肝脏复发。1年和2年生存率分别为80%和21.4%。这种免疫疗法可以预防术后肝转移，但不能控制局部复发。(2)对不能手术切除的24例胰腺癌患者进行了肿瘤多肽疫苗治疗的I期研究。3毫克多肽与弗氏不完全佐剂一起皮下注射。未见严重不良反应。10例患者中有7例注射部位有红肿。10例患者中有3例为NC，7例为PD。1例NC患者存活12个月。这种疫苗疗法可能有效地控制局部病变，包括区域淋巴转移。

项目成果

Yoshimura K, Hazama S, Iizuka N, Yoshino S, Yamamoto K, Muraguchi M, Ohmoto Y, Noma T, Oka M: "Successful immunogene therapy using colon cancer cells (colon 26) transfected with plasmid vector containing mature interleukin-18 cDNA and the Igkappa leader s

Yoshimura K、Hazama S、Iizuka N、Yoshino S、Yamamoto K、Muraguchi M、Ohmoto Y、Noma T、Oka M：“使用含有成熟白细胞介素 18 cDNA 的质粒载体转染的结肠癌细胞（结肠 26）进行成功的免疫基因治疗

Ohno R, Yamaguchi Y, Toge T, Kinouchi T, Kotake T, Shibata M, Kiyohara Y, Ikeda S, Fukui I, Gohchi A, Sugiyama Y, Saji S, Hazama S, Oka M, Ohnishi K, Ohhashi Y, Tsukagoshi S, Taguchi T: "A dose-escalation and pharmacokinetic study of subcutaneously admini

Ohno R、Yamaguchi Y、Toge T、Kinouchi T、Kotake T、Shibata M、Kiyohara Y、Ikeda S、Fukui I、Gohchi A、Sugiyama Y、Saji S、Hazama S、Oka M、Ohnishi K、Ohhashi Y、Tsukagoshi S

Iizuka N, Oka M, et al.: "Use of oligonucleotide microarray as a novel approach for prediction of early intrahepatic recurrence in hepatocellular carcinoma after curative resection"Lancet. 361. 923-929 (2003)

Iizuka N、Oka M 等人：“使用寡核苷酸微阵列作为预测治愈性切除后肝细胞癌早期肝内复发的新方法”《柳叶刀》。

Suzuki N, Tanaka S, Hida N, Mine T, Yamamoto K, Oka M, Itoh K: "Detection of peptide-specific cytotoxic T lymphocyte precursors used for specific immunotherapy for pancreatic cancer"International Journal of Cancer. Mar 1 ; 98(1). 45-50 (2002)

Suzuki N、Tanaka S、Hida N、Mine T、Yamamoto K、Oka M、Itoh K：“用于胰腺癌特异性免疫治疗的肽特异性细胞毒性 T 淋巴细胞前体的检测”国际癌症杂志。

Yoshino S, Tabata T, Hazama S, Iizuka N, Yamamoto K, Hirayama M, Tangoku A, Oka M: "Immunoregulatory effects of the antitumor polysaccharide lentinan on Th1/Th2 balance in patients with digestive cancers"Anticancer Research. 20. 4707-4711 (2000)

Yoshino S、Tabata T、Hazama S、Iizuka N、Yamamoto K、Hirayama M、Tangoku A、Oka M：“抗肿瘤多糖香菇多糖对消化道癌症患者 Th1/Th2 平衡的免疫调节作用”抗癌研究。